Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HCC1806 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.3241 0.57687
Hs 578T Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.3466 0.60172
SK-BR-3 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.4717 0.58287
HCC70 Ipatasertib
3.1623
AKT
PI3K/mTOR
 -0.0455 0.21194
HCC1806 Abemaciclib
3.1623
CDK4/6
Cell cycle
 0.1267 0.14911
Hs 578T Saracatinib
3.1623
SRC
MAPK/nRTK
 0.6283 0.02597
Hs 578T Pictilisib
3.1623
pan PI3K
PI3K/mTOR
 0.3434 0.09268
MCF 10A ABT-737
3.1623
Bcl2/XL
Misc
 0.9604 0.01007
HCC1806 Pictilisib
3.1623
pan PI3K
PI3K/mTOR
 0.7587 0.01597
Hs 578T Alpelisib
3.1623
PI3Ka
PI3K/mTOR
 0.8050 0.00474
MCF7 Buparlisib
3.1623
pan PI3K
PI3K/mTOR
 -0.2116 0.31687
MCF 10A Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 0.1747 0.16395
Hs 578T Topotecan
3.1623
Topo I
Chemotherapy
 -0.4314 0.78405
Hs 578T A-1210477
3.1623
Mcl-1
Misc
 1.0615 0.00422
MCF 10A Saracatinib
3.1623
SRC
MAPK/nRTK
 0.6667 0.00620
MCF7 Etoposide
3.1623
Topo II
Chemotherapy
 -0.0441 0.04288
HCC1806 Vorinostat
3.1623
HDAC
Misc
 0.1581 0.17812
HCC1806 Ceritinib
3.1623
ALK
RTK
 0.1763 0.12321
MCF7 Saracatinib
3.1623
SRC
MAPK/nRTK
 0.3461 0.04415
SK-BR-3 Bleomycin
3.1623
Radiation
Misc
 0.3155 0.14104
MCF 10A Vorinostat
3.1623
HDAC
Misc
 0.4182 0.00189
MCF7 Vorinostat
3.1623
HDAC
Misc
 -0.0037 0.26078
Hs 578T AZD7762
3.1623
CHK1/2
Cell cycle
 -0.3399 0.65876
HCC70 Pictilisib
3.1623
pan PI3K
PI3K/mTOR
 -0.3208 0.27494
HCC70 Buparlisib
3.1623
pan PI3K
PI3K/mTOR
 -0.5323 0.53772